Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTEĀ® AMG 330.

Laszlo GS, Beddoe ME, Godwin CD, Bates OM, Gudgeon CJ, Harrington KH, Walter RB.

Haematologica. 2019 Feb;104(2):e59-e62. doi: 10.3324/haematol.2018.202069. Epub 2018 Aug 16. No abstract available.

2.

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB.

Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31. No abstract available.

3.

Gemtuzumab ozogamicin in acute myeloid leukemia.

Godwin CD, Gale RP, Walter RB.

Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13. Review.

PMID:
28607471
4.

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.

Godwin CD, McDonald GB, Walter RB.

Blood. 2017 Apr 20;129(16):2330-2332. doi: 10.1182/blood-2017-01-762419. Epub 2017 Feb 2. No abstract available.

5.

Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.

Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB.

Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11. No abstract available.

6.

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, Sorror ML, Deeg HJ, Storb R, Appelbaum FR.

Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8. doi: 10.1016/j.bbmt.2014.09.022. Epub 2014 Sep 30.

7.

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.

Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM.

Leukemia. 2015 Jan;29(1):137-44. doi: 10.1038/leu.2014.173. Epub 2014 Jun 3.

8.

Synergistic postprandial blood glucose modulatory properties of Vernonia amygdalina (Del.), Gongronema latifolium (Benth.) and Occimum gratissimum (Linn.) aqueous decoctions.

Ejike CE, Awazie SO, Nwangozi PA, Godwin CD.

J Ethnopharmacol. 2013 Aug 26;149(1):111-6. doi: 10.1016/j.jep.2013.06.009. Epub 2013 Jun 14.

PMID:
23770031
9.

Abnormalities of blink rate in psychoses: a preliminary report.

Helms PM, Godwin CD.

Biol Psychiatry. 1985 Jan;20(1):103-6. No abstract available.

PMID:
3965034
10.

Lithium-carbamazepine neurotoxicity and risk factors.

Shukla S, Godwin CD, Long LE, Miller MG.

Am J Psychiatry. 1984 Dec;141(12):1604-6.

PMID:
6439058
11.

The dexamethasone suppression test in acute mania.

Godwin CD.

J Affect Disord. 1984 Dec;7(3-4):281-6.

PMID:
6241210
12.

Predictive value of the dexamethasone suppression test in mania.

Godwin CD, Greenberg LB, Shukla S.

Am J Psychiatry. 1984 Dec;141(12):1610-2.

PMID:
6150650
13.

Consistent dexamethasone suppression test results with mania and depression in bipolar illness.

Godwin CD, Greenberg LB, Shukla S.

Am J Psychiatry. 1984 Oct;141(10):1263-5.

PMID:
6486264
14.

Case report of tricyclic-induced delirium at a therapeutic drug concentration.

Godwin CD.

Am J Psychiatry. 1983 Nov;140(11):1517-8.

PMID:
6625006

Supplemental Content

Loading ...
Support Center